The SGLT-2 inhibitors are a relatively new treatment for type 2 diabetes, and the authors of this study felt their use had not yet been adequately studied in the elderly. They examined the effect of one SGLT-2 inhibitor, dapagliflozin (brand name Farxiga) to assess its effects on blood glucose control and kidney health in senior patients. Read more